정보마당

No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

9/1

Roche

Simcere Zaiming

SIM0660

CD79a × CD19 × CD3 TsAb

Immunology,

Oncology

B-cell-mediated

    diseases

Preclinical

1,530

2

9/1

ZoeNCure Therapeutics

Styx Biotechnologies

n/d

ADC

Oncology

Solid tumors

Preclinical

n/d

3

9/2

Novartis

Alteogen

ALT-B4

recombinant human hyaluronidase developed using Hybrozyme™ platform

-

-

-

3,223

4

9/2

Evotec

Plectonic

Evotec: BiTco CD2 costimulatory bispecific platform

Plectonic: LOGIBODY® logic-gated DNA–protein immunotherapy platform

Collaboration: next-generation TCE discovery

Oncology

Solid tumors

Discovery

n/d

5

9/3

GSK

Hutchmed

HMPL-A830

EGFR-targeted KRASi ATTC(Antibody-Targeted Therapy Conjugate)

Oncology

Solid tumors

Phase 1

1,295

6

9/3

Menarini Group

Gan & Lee
Pharmaceuticals

Bofanglutide

GLP-1R agonist

Metabolic disorder

Obesity, T2D

Phase 3

843

7

9/7

Medicus Pharma

Pfizer

CD228V
(PF-08046031)

CD228 ADC

Oncology

Solid tumors

Phase 1

1,000+

8

9/7

Aceso Therapeutics

Aptar Pharma

ACT-101

CFTR mRNA-stabilizing ASO

Respiratory disease

Cystic fibrosis

Preclinical

n/d

9

9/15

Eli Lilly

QurCan Therapeutics

‘TERP™’ platform

Polymer–lipid nanoparticle–mediated nucleic acid delivery platform

Neurology

CNS, PNS diseases

Discovery

237+

10

9/15

GSK

Chimagen Biosciences

n/d

Trispecific TCE

Oncology

Multiple myeloma

Preclinical

750

11

9/16

Novo Nordisk

Anthropic

‘Claude Science’ platform

AI-powered scientific reasoning for drug discovery platform

-

-

Discovery

n/d

12

9/17

Novo Nordisk

Orbis Medicines

‘nGen’ Platform

AI-enabled macrocycle drug discovery platform

Cardiometabolic disease

-

Discovery

1,400

13

9/17

Roche

Dualitas Therapeutics

‘DualScreen™’ platform

Proximity-driven bispecific antibody discovery platform

Immunology &
Inflammation

-

Discovery

1,000

14

9/21

Novo Nordisk

Kallyope

K-554

Non-incretin peptide

Metabolic disorder

Obesity

Preclinical

n/d

n/d

2 undisclosed non-incretin small-molecule programs

Metabolic disorder

Obesity

Preclinical

15

9/22

Boehringer Ingelheim

Envisagenics

‘SpliceCore’ platform

AI-driven RNA-splicing target discovery platform

Oncology

n/d

Discovery

1,000

16

9/22

Novartis

BoomRay Pharmaceuticals

n/d

RPT

Oncology

n/d

Preclinical

900

17

9/24

Roche

Atavistik Bio

‘AMPS’ platform

Allosteric small molecule discovery platform

CVRM

(Cardiovascular, Renal, Metabolic disease)

n/d

Discovery

1,970

18

9/24

Eli Lilly

InnoCare Pharma

n/d

Compounds against ≤5 undisclosed targets

n/d

n/d

Discovery

3,250+

19

9/25

Genentech
(Roche)

Earendil Labs

n/d

AI-enabled bispecific antibody discovery platform

Oncology

n/d

Discovery

1,555

20

9/25

Shanghai Henlius Biotech

Amberstone Biosciences

‘T-MATE’ platform

Up to 2 pH-gated TCE programs

Oncology

Solid tumors

Preclinical

880

21

9/25

Novo Nordisk

Nanexa

‘PharmaShell®’ platform

ALD-based long-acting injectable delivery platform

Cardiometabolic disease

Obesity, T2D, Other Cardiometabolic disease

Discovery

1,326

22

9/28

MSD

SciBrunch Therapeutics

SPR2015

KRAS G12D(ON) inhibitor

Oncology

KRAS G12D mut. cancers

Preclinical

2,130

23

9/29

Novo Nordisk

Hengrui Pharma

HRS-1596

GLP-1/GIP dual receptor agonist

Metabolic disorder

Obesity, T2D

IND cleared (China)

2,600

24

9/29

Novasenta*

Corner Therapeutics

‘StarX’ platform

‘T Deplete’ platform

Targeted mRNA-induced Th17 cell apoptosis

Antibody-mediated pathogenic Th17 cell depletion

Immunology

Autoimmune disease

Preclinical

n/d

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

9/17

North Immunology*

Aethlon Medical

NOR-101

IL-13 x IL-18 BsAb

Immunology

Atopic Dermatitis

Preclinical

n/d

2

9/21

Telix Pharmaceuticals

Isotope Technologies Munich SE

ITM-11

SSTR-targeted RPT using β-emitting 177Lu-edotreotide

Oncology

G1–G2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Phase 3

2,350